AtriCure, Inc. (ATRC) Price Prediction 2026–2050

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.

It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments.

The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure, Inc. (ATRC) operates in the Healthcare sector and trades with a current price of $28.29 and a market cap of $1.43B. It is ranked #2264 by market capitalization.

The price outlook is positive over the longer term, with the forecast showing a rising average price through 2030 and beyond. The 2030 average price is $39.53, with a range to $54.78, and the 2050 average price is $168.52, with a wide upside to $283.39. Returns implied by the forecast trend from 2026 onward suggest notable upside, culminating in an average price of $168.52 by 2050 and a maximum scenario of $283.39.

In the near term, the 2026 forecast estimates an average price of $28.29, within a 30-day range of $24.69 to $32.41, indicating a neutral starting point. The long-run trajectory points to a bullish path from 2029 onward, reinforcing the potential for meaningful appreciation by mid-century.

The multi-year forecast points to a bullish trajectory, with notable upside through 2030, 2040, and 2050. The 2030 average price is $39.53 with a max of $54.78 and a min of $30.48, corresponding to a 39.7% ROI and a bullish sentiment. By 2040, the average climbs to $92.72, with a max of $144.83 and a min of $64.36, yielding a 227.8% ROI and continuing bullish sentiment.

In 2050, the average is projected at $168.52, with a max of $283.39 and a min of $108.15, for a 495.7% ROI and a sustained bullish stance.

These figures illustrate a steady, long-run upward trajectory in the forecast, underscoring a strong long-term equity profile. However, these are estimates and not guarantees, and actual results will depend on many factors beyond the numbers shown. The forecast for 2026 shows a neutral starting point, while the later years show a bullish tilt with rising averages and higher potential upside.